Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Release Date: December 23, 2025

Expiration Date: December 23, 2026

Activity Overview

Sickle cell disease (SCD) has entered a transformative era marked by significant progress in disease-modifying therapy (DMT) and curative strategies. This educational program brings together leading SCD experts to explore the latest evidence, real-world insights, and clinical considerations shaping modern SCD management. Drawing on evolving data and extensive experience caring for individuals with SCD, faculty will discuss therapies that are altering the natural history of the disease and expanding possibilities for long-term health.

Participants will hear experts break down clinical trial data, compare mechanisms of DMT, and provide practical commentary on integrating these options into everyday practice. The program will also highlight advances in curative approaches—including hematopoietic stem cell transplantation and gene-based therapies—emphasizing patient selection, safety considerations, evolving protocols, and the real-world challenges of implementation and access. This program aims to equip clinicians with the knowledge and expert perspective needed to navigate current options, evaluate emerging therapies, and support patients in making informed decisions about transformative and curative care pathways in SCD.

Target Audience

This educational activity is primarily directed toward hematologists, NPs, and PAs. Other clinicians involved in the care of SCD will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess clinical trial data for therapies for SCD

• Integrate appropriate therapeutic approaches into individualized management plans for patients with SCD

• Design individualized multidisciplinary management plans for patients with SCD